These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 19661804

  • 1. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, Eritoran Sepsis Study Group.
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J.
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [Abstract] [Full Text] [Related]

  • 3. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
    Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM, Eritoran Sepsis Study Group.
    Shock; 2011 Oct; 36(4):327-31. PubMed ID: 21701421
    [Abstract] [Full Text] [Related]

  • 4. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
    Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, van Roon EN, Buter H, Bruins N, Egbers PH, Gerritsen RT, Koetsier PM, Kingma WP, Kuiper MA, Ince C.
    Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
    [Abstract] [Full Text] [Related]

  • 5. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, ACCESS Study Group.
    JAMA; 2013 Mar 20; 309(11):1154-62. PubMed ID: 23512062
    [Abstract] [Full Text] [Related]

  • 6. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Bennett-Guerrero E, Grocott HP, Levy JH, Stierer KA, Hogue CW, Cheung AT, Newman MF, Carter AA, Rossignol DP, Collard CD.
    Anesth Analg; 2007 Feb 20; 104(2):378-83. PubMed ID: 17242095
    [Abstract] [Full Text] [Related]

  • 7. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M, LaRosa SP.
    Expert Rev Anti Infect Ther; 2011 May 20; 9(5):507-20. PubMed ID: 21609262
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
    Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J, Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators.
    Crit Care Med; 2009 Nov 20; 37(11):2929-38. PubMed ID: 19770753
    [Abstract] [Full Text] [Related]

  • 9. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
    Rossignol DP, Wong N, Noveck R, Lynn M.
    Innate Immun; 2008 Dec 20; 14(6):383-94. PubMed ID: 19039062
    [Abstract] [Full Text] [Related]

  • 10. Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
    Barochia AV, Cui X, Natanson C, Eichacker PQ.
    Crit Care Med; 2010 Jan 20; 38(1):306-8. PubMed ID: 20023474
    [No Abstract] [Full Text] [Related]

  • 11. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators.
    Crit Care Med; 2004 Feb 20; 32(2):332-41. PubMed ID: 14758145
    [Abstract] [Full Text] [Related]

  • 12. Relationship of pulmonary artery catheter use to mortality and resource utilization in patients with severe sepsis.
    Yu DT, Platt R, Lanken PN, Black E, Sands KE, Schwartz JS, Hibberd PL, Graman PS, Kahn KL, Snydman DR, Parsonnet J, Moore R, Bates DW, AMCC Sepsis Project Working Group.
    Crit Care Med; 2003 Dec 20; 31(12):2734-41. PubMed ID: 14668609
    [Abstract] [Full Text] [Related]

  • 13. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.
    Eid A, Wiedermann CJ, Kinasewitz GT.
    Anesth Analg; 2008 Nov 20; 107(5):1633-8. PubMed ID: 18931224
    [Abstract] [Full Text] [Related]

  • 14. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J, Glaxo Wellcome International Septic Shock Study Group.
    Crit Care Med; 2004 Jan 20; 32(1):1-12. PubMed ID: 14707554
    [Abstract] [Full Text] [Related]

  • 15. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure.
    Karvellas CJ, Pink F, McPhail M, Austin M, Auzinger G, Bernal W, Sizer E, Kutsogiannis DJ, Eltringham I, Wendon JA.
    Crit Care Med; 2010 Jan 20; 38(1):121-6. PubMed ID: 19770744
    [Abstract] [Full Text] [Related]

  • 16. Practice and perception--a nationwide survey of therapy habits in sepsis.
    Brunkhorst FM, Engel C, Ragaller M, Welte T, Rossaint R, Gerlach H, Mayer K, John S, Stuber F, Weiler N, Oppert M, Moerer O, Bogatsch H, Reinhart K, Loeffler M, Hartog C, German Sepsis Competence Network (SepNet).
    Crit Care Med; 2008 Oct 20; 36(10):2719-25. PubMed ID: 18766100
    [Abstract] [Full Text] [Related]

  • 17. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW, MAB-T88 Sepsis Study Group.
    Crit Care Med; 2003 Feb 20; 31(2):419-27. PubMed ID: 12576946
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA.
    Crit Care Med; 2001 Nov 20; 29(11):2081-9. PubMed ID: 11700399
    [Abstract] [Full Text] [Related]

  • 19. Reduction in mortality associated with statin therapy in patients with severe sepsis.
    Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM.
    Pharmacotherapy; 2009 Jun 20; 29(6):621-30. PubMed ID: 19476415
    [Abstract] [Full Text] [Related]

  • 20. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP.
    Crit Care Med; 1994 Nov 20; 22(11):1720-8. PubMed ID: 7956274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.